“…In the preceding decades, nano-carriers have gained popularity for the delivery of therapeutically active compounds into pulmonary system, in order to fulfil several requirements including; shielding drug degradation, drug loading ability, sustained release, biodegradation and biocompatibility; as well as formulation stability during nebulization using various nebulizers. Various lipid-based formulations fulfil these requirements and have successfully delivered APIs (active pharmaceutical ingredients) into the pulmonary system, these include: liposomes and proliposomes , Elhissi, 2017, Elhissi et al, 2011, Gala et al, 2015, Bnyan et al, 2020, transfersomes and protransfersomes (Bnyan et al, 2019, Khan et al, 2020a, Subramanian et al, 2016, Bnyan et al, 2018, niosomes and proniosomes (Najlah et al, 2015, Muzzalupo andMazzotta, 2019), ethosomes and nanoemulsions (Nasri et al, 2020, Pavoni et al, 2020, Nesamony et al, 2014, polymeric nanoparticles (Jarai et al, 2020, d'Angelo et al, 2015 and solid lipid nanoparticles (Liu et al, 2008, Esmaeili et al, 2016. Lipid nanoparticles are a popular research avenue for the delivery of hydrophobic drugs.…”